Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17169293 | METHOD OF SCREENING FOR COLORECTAL CANCER | February 2021 | November 2022 | Abandon | 60 | 2 | 1 | No | No |
| 17247534 | Marker and diagnosis method for noninvasive diagnosis of myocardial infarction | December 2020 | June 2023 | Allow | 30 | 2 | 1 | Yes | No |
| 17119167 | COMPOSITIONS AND METHODS FOR ASSESSING ACUTE REJECTION IN RENAL TRANSPLANTATION | December 2020 | April 2024 | Abandon | 40 | 2 | 1 | No | No |
| 16953480 | CIRCULATING RNA SIGNATURES SPECIFIC TO PREECLAMPSIA | November 2020 | November 2022 | Allow | 24 | 2 | 1 | Yes | No |
| 17097705 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | November 2020 | September 2022 | Abandon | 22 | 0 | 1 | No | No |
| 17053572 | METHOD FOR PREDICTING THE RISK OF LATE-ONSET ALZHEIMER'S DISEASES | November 2020 | September 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16971692 | BIOMARKER FOR DETECTING A POSSIBLE INCOMPATABILITY WITH RESPECT TO METAL IMPLANTS | November 2020 | November 2022 | Allow | 27 | 2 | 1 | Yes | No |
| 17066189 | Left-Right Gene Expression Signature for Triple Negative Breast Cancer | October 2020 | October 2023 | Abandon | 36 | 2 | 1 | No | No |
| 17035179 | DNA Damage Repair Inhibitors for Treatment of Cancer | September 2020 | December 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16980121 | METHOD FOR PREDICTING PROGRESSION TO ACTIVE TUBERCULOSIS DISEASE | September 2020 | November 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16995180 | METHODS AND SYSTEMS FOR DETECTION OF PROSTATE CANCER BY DNA METHYLATION ANALYSIS | August 2020 | March 2022 | Allow | 19 | 1 | 1 | Yes | No |
| 16963355 | USE OF CFDNA FRAGMENTS AS BIOMARKERS IN PATIENTS AFTER ORGAN TRANSPLANTATION | July 2020 | March 2024 | Allow | 43 | 3 | 1 | No | No |
| 16928828 | BIOMARKER FOR PREDICTING RISK OF RECURRENCE IN PATIENTS WITH PAROXYSMAL ATRIAL FIBRILLATION | July 2020 | March 2023 | Allow | 36 | 3 | 0 | Yes | No |
| 16923005 | NON-INVASIVE PRENATAL TESTING AT EARLY STAGE OF PREGNANCY | July 2020 | November 2023 | Allow | 41 | 3 | 1 | Yes | No |
| 16919095 | SUPPORT BACKING STRIP TECHNOLOGY AND METHOD FOR NON-DESTRUCTIVE IDENTIFICATION OF LATENT PRINT AND DNA DEPOSITED ON ADHESIVE MATERIALS | July 2020 | April 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16954183 | ASSESSING GRAFT SUITABILITY FOR TRANSPLANTATION | June 2020 | March 2024 | Allow | 45 | 4 | 1 | Yes | No |
| 16763714 | BIOMARKER INDICATING RESPONSE TO POZIOTINIB THERAPY FOR CANCER | May 2020 | February 2023 | Abandon | 33 | 0 | 1 | No | No |
| 16871951 | DIAGNOSTIC ASSAY FOR TISSUE TRANSPLANTATION STATUS | May 2020 | May 2023 | Abandon | 36 | 1 | 1 | No | No |
| 16762820 | Sensitive and Accurate Genome-wide Profiling of RNA Structure In Vivo | May 2020 | May 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16852663 | NONINVASIVE DIAGNOSIS OF FETAL ANEUPLOIDY BY SEQUENCING | April 2020 | March 2024 | Allow | 47 | 3 | 0 | Yes | No |
| 16833587 | METHOD FOR PREDICTING ORGAN TRANSPLANT REJECTION USING NEXT-GENERATION SEQUENCING | March 2020 | January 2023 | Abandon | 34 | 1 | 1 | No | No |
| 16822839 | BILIARY TRACT CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | March 2020 | June 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16817729 | KIT FOR DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS AND PROBE FOR THE DETECTION AND QUANTIFICATION OF THE METHYLATION LEVEL OF AN IFI44L FRAGMENT | March 2020 | May 2022 | Allow | 26 | 2 | 0 | No | No |
| 16644313 | ASSOCIATION OF GENETIC VARIATIONS TO DIAGNOSE AND TREAT ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) | March 2020 | October 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16808095 | PROSTATE CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | March 2020 | June 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16807528 | MIRNA in Gulf War Illness | March 2020 | May 2022 | Abandon | 26 | 1 | 0 | No | No |
| 16803390 | ESOPHAGEAL CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | February 2020 | August 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16800755 | LUNG CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | February 2020 | August 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16797625 | BREAST CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | February 2020 | June 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16639103 | Application Of Lung Cancer-Associated MicroRNA Molecular Marker In Serum Exosome And Detection Kit Using Same | February 2020 | October 2023 | Abandon | 44 | 2 | 1 | No | No |
| 16789943 | STOMACH CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | February 2020 | June 2022 | Allow | 28 | 1 | 1 | No | No |
| 16789986 | COLORECTAL CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | February 2020 | June 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16785790 | APPARATUS, KITS AND METHODS FOR THE PREDICTION OF ONSET OF SEPSIS | February 2020 | March 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16785233 | LIVER CANCER DETECTION KIT OR DEVICE, AND DETECTION METHOD | February 2020 | July 2022 | Allow | 29 | 2 | 1 | No | No |
| 16636162 | BIOMARKERS FOR ASSESSING THE RESPONSE STATUS FOR TREATMENT OF INFLAMMATORY CONDITION OR DISEASE AFFECTING THE DIGESTIVE TRACT SUCH AS INFLAMMATORY BOWEL DISEASE IN HUMAN PATIENTS | February 2020 | April 2024 | Allow | 51 | 2 | 1 | Yes | No |
| 16778490 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING DEVELOPMENTAL DISORDERS | January 2020 | November 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16630127 | SMALL RNA PREDICTORS FOR HUNTINGTON'S DISEASE | January 2020 | October 2024 | Abandon | 57 | 3 | 1 | Yes | Yes |
| 16730949 | CELL-FREE DNA FOR ASSESSING AND/OR TREATING CANCER | December 2019 | November 2020 | Allow | 11 | 2 | 0 | Yes | No |
| 16730938 | CELL-FREE DNA FOR ASSESSING AND/OR TREATING CANCER | December 2019 | December 2020 | Allow | 12 | 1 | 1 | Yes | No |
| 16624500 | BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF FIBROTIC LUNG DISEASE | December 2019 | November 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16721038 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CALR MUTATIONS IN MYELOPROLIFERATIVE DISEASES | December 2019 | March 2022 | Abandon | 27 | 1 | 1 | No | No |
| 16624779 | PCR PRIMER PAIR AND APPLICATION THEREOF | December 2019 | June 2023 | Allow | 41 | 2 | 1 | Yes | No |
| 16624061 | Methods and Compositions For Predicting Chronic Lung Allograft Dysfunction | December 2019 | April 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16617980 | GENETIC IDENTIFICATION OF PISCIRICKETTSIA SALMONIS RESISTANT SALMONIDS | November 2019 | June 2024 | Allow | 55 | 2 | 2 | Yes | No |
| 16693117 | TUMOR ORGANOID CULTURE COMPOSITIONS, SYSTEMS, AND METHODS | November 2019 | December 2022 | Allow | 37 | 4 | 1 | Yes | No |
| 16615659 | Methods of Diagnosing Intervertebral Disc Disease And Chondrodystrophy In Canines | November 2019 | March 2023 | Allow | 40 | 2 | 1 | Yes | No |
| 16683588 | DNA METHYLATION IN COLORECTAL AND BREAST CANCER DIAGNOSTIC METHODS | November 2019 | November 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16667932 | METHODS FOR DETERMINING RESPONSIVENESS TO MEK/ERK INHIBITORS | October 2019 | November 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16596481 | DIAGNOSIS OF SEPSIS | October 2019 | August 2022 | Allow | 60 | 1 | 1 | Yes | No |
| 16603613 | METHODS AND KITS FOR EVALUATING ZINC LEVELS IN MILK | October 2019 | August 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16590182 | COMPOSITIONS AND METHODS FOR ANALYZING HETEROGENEOUS SAMPLES | October 2019 | November 2021 | Abandon | 25 | 0 | 1 | No | No |
| 16499105 | METHODS FOR ASSESSING RISK OF OR DIAGNOSING GENETIC DEFECTS BY IDENTIFYING DE NOVO MUTATIONS OR SOMATIC MOSAIC VARIANTS IN SPERM OR SOMATIC TISSUES | September 2019 | November 2022 | Abandon | 37 | 2 | 1 | No | No |
| 16496154 | ANALYSIS AND PREDICTION OF TRAUMATIC BRAIN INJURY AND CONCUSSION SYMPTOMS | September 2019 | June 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16516663 | DIAGNOSIS AND TREATMENT OF PSORIATIC ARTHRITIS | July 2019 | October 2021 | Allow | 27 | 1 | 1 | Yes | No |
| 16419958 | METHODS AND COMPOSITIONS FOR DETERMINING RESPONSIVENESS TO ANTIBODY THERAPY | May 2019 | October 2023 | Abandon | 53 | 3 | 1 | Yes | No |
| 16405812 | INHIBITING THE ONSET OF GOUT | May 2019 | April 2021 | Allow | 23 | 2 | 1 | Yes | No |
| 16373996 | METHODS FOR PROFILING AND QUANTITATING CELL-FREE RNA | April 2019 | September 2021 | Abandon | 30 | 0 | 1 | No | No |
| 16371420 | COMPOSITIONS AND METHODS FOR DETERMINING LIKELIHOOD OF AN INCREASED SUSCEPTIBILITY TO CONTRACTING JOHNE'S DISEASE | April 2019 | April 2020 | Allow | 12 | 0 | 1 | Yes | No |
| 16335996 | DIAGNOSIS, PROGNOSIS AND TREATMENT FOR SCHIZOPHRENIA AND SCHIZOAFFECTIVE PSYCHOSIS | March 2019 | March 2022 | Abandon | 36 | 1 | 1 | No | No |
| 16351378 | METHOD TO PERFORM MEDICAL PROCEDURES ON BREAST CANCER PATIENTS GUIDED BY AN SNP DERIVED POLYGENIC RISK SCORE | March 2019 | February 2023 | Abandon | 48 | 2 | 1 | No | No |
| 16286975 | GENETIC MARKERS ASSOCIATED WITH ENDOMETRIOSIS AND USE THEREOF | February 2019 | March 2022 | Abandon | 36 | 1 | 1 | Yes | No |
| 16324467 | GRAPHENE NANOSENSOR FOR DETECTING TARGET RNA | February 2019 | September 2022 | Abandon | 44 | 3 | 0 | No | No |
| 16321022 | Application of SNP (Single Nucleotide Polymorphism) Loci of Whole Genome of Yak, Primer Group for Detection and Kit | January 2019 | December 2020 | Allow | 22 | 2 | 1 | Yes | No |
| 16317518 | Method of Identifying a Subject Having a Bacterial Infection | January 2019 | September 2021 | Allow | 33 | 2 | 1 | Yes | No |
| 16241565 | SYSTEMS AND METHODS FOR DETERMINING A TREATMENT COURSE OF ACTION | January 2019 | February 2023 | Allow | 50 | 4 | 1 | Yes | No |
| 16239129 | Methods and compositions for screening and treating developmental disorders | January 2019 | January 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16235247 | METHODS FOR PREDICTING ANTI-CANCER RESPONSE | December 2018 | November 2021 | Allow | 35 | 1 | 1 | Yes | No |
| 16218175 | DNA SEQUENCING BY NANOPORE USING MODIFIED NUCLEOTIDES | December 2018 | November 2021 | Abandon | 35 | 3 | 0 | Yes | No |
| 16308564 | METHODS AND KITS COMPRISING GENE SIGNATURES FOR STRATIFYING BREAST CANCER PATIENTS | December 2018 | April 2022 | Allow | 40 | 3 | 1 | Yes | No |
| 16308315 | METHODS FOR DETECTING STRUCTURAL VARIANTS IN NEURODEGENERATIVE DISEASE | December 2018 | January 2021 | Allow | 25 | 2 | 1 | Yes | No |
| 16207534 | GENETIC POLYMORPHISMS ASSOCIATED WITH VENOUS THROMBOSIS, METHODS OF DETECTION AND USES THEREOF | December 2018 | March 2021 | Allow | 27 | 2 | 1 | No | No |
| 16197319 | Methods for Enriching Microbial Cell-Free DNA in Plasma | November 2018 | April 2024 | Abandon | 60 | 4 | 0 | No | No |
| 16098500 | PROFILING MICROVESICLE NUCLEIC ACIDS AND USES THEREOF AS SIGNATURES IN DIAGNOSIS OF RENAL TRANSPLANT REJECTION | November 2018 | August 2021 | Allow | 34 | 1 | 1 | No | No |
| 16168525 | METHODS AND COMPOSITIONS FOR THE DETECTION, CLASSIFICATION, AND DIAGNOSIS OF SCHIZOPHRENIA | October 2018 | January 2023 | Abandon | 51 | 2 | 2 | Yes | No |
| 16159373 | HENT1 PLUS MATE1/OCT2 POLYMORPHISMS PREDICT EFFICACY AND TOXICITY OF TAS-102 IN METASTATIC COLORECTAL CANCER PATIENTS | October 2018 | January 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16154023 | METHODS FOR DETECTING EPIGENETIC MODIFICATIONS | October 2018 | June 2021 | Allow | 32 | 1 | 1 | Yes | No |
| 16091731 | SF3B1 SUPPRESSION AS A THERAPY FOR TUMORS HARBORING SF3B1 COPY LOSS | October 2018 | May 2022 | Abandon | 43 | 2 | 1 | Yes | No |
| 16149492 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | October 2018 | November 2020 | Allow | 25 | 1 | 1 | No | No |
| 16149653 | METHOD OF DIAGNOSING NEOPLASMS - II | October 2018 | February 2022 | Abandon | 40 | 2 | 0 | No | No |
| 16141371 | METHODS FOR IDENTIFYING AND TREATING KAWASAKI DISEASE PATIENTS WITH INTRAVENOUS IMMUNOGLOBULIN RESISTANCE | September 2018 | December 2020 | Abandon | 27 | 0 | 1 | No | No |
| 16088359 | IDENTIFICATION OF UNIQUE BLOOD-BASED GENE EXPRESSION PROFILES IN CHILDREN WITH REGRESSIVE AUTISM SPECTRUM DISORDER (ASD) AND ILEOCOLITIS | September 2018 | September 2021 | Allow | 36 | 2 | 1 | Yes | No |
| 16083055 | COMPOSITIONS FOR CHARACTERIZING DEVELOPMENT OF ESOPHAGEAL ADENOCARCINOMA IN PATIENTS AND METHODS OF USE THEREOF | September 2018 | September 2021 | Allow | 36 | 2 | 1 | Yes | No |
| 16076775 | METHODS FOR ASSESSING THE TREATMENT RESPONSE OF TNBC PATIENTS TO NEO-ADJUVANT CHEMOTHERAPY BY ANALYSING CPG METHYLATION | August 2018 | September 2021 | Allow | 38 | 2 | 1 | Yes | No |
| 16073564 | COMPOSITIONS AND METHODS FOR SCREENING PEDIATRIC GLIOMAS AND METHODS OF TREATMENT THEREOF | July 2018 | December 2020 | Abandon | 29 | 0 | 2 | No | No |
| 16071999 | PLANT BREEDING USING NEXT GENERATION SEQUENCING | July 2018 | November 2020 | Abandon | 28 | 0 | 1 | No | No |
| 16031218 | DISEASE RISK FACTORS AND METHODS OF USE | July 2018 | February 2021 | Allow | 31 | 1 | 1 | Yes | No |
| 16025769 | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE | July 2018 | September 2021 | Allow | 38 | 2 | 1 | Yes | No |
| 16067139 | BIOMARKER FOR BREAST CANCER | June 2018 | October 2020 | Abandon | 28 | 0 | 1 | No | No |
| 16021261 | METHOD OF IDENTIFYING DISEASE RISK FACTORS | June 2018 | August 2020 | Allow | 25 | 1 | 1 | Yes | No |
| 16019079 | METHODS OF DIAGNOSING AND TREATING CANCER BY DETECTION OF CHROMOSOMAL ABNORMALITIES | June 2018 | November 2020 | Abandon | 29 | 1 | 1 | No | No |
| 16065662 | DISTINGUISHING METASTATIC-LETHAL PROSTATE CANCER FROM INDOLENT PROSTATE CANCER USING METHYLATION STATUS OF EPIGENETIC MARKERS | June 2018 | March 2021 | Abandon | 33 | 1 | 1 | No | No |
| 16006641 | MARKERS OF TUMOR CELL RESPONSE TO ANTI-CANCER THERAPY | June 2018 | July 2020 | Abandon | 25 | 1 | 0 | No | No |
| 16006361 | DIAGNOSTIC METHODS FOR DETERMINING PROGNOSIS OF NON-SMALL CELL LUNG CANCER | June 2018 | January 2020 | Allow | 19 | 1 | 0 | No | No |
| 16061046 | QTLS ASSOCIATED WITH AND METHODS FOR IDENTIFYING LODGING RESISTANCE IN SOYBEAN | June 2018 | February 2021 | Allow | 32 | 2 | 1 | Yes | No |
| 16060620 | BLADDER CANCER DETECTION USING MICROSATELLITE ANALYSIS IN PAIRED BUCCAL SWAB AND URINE SAMPLES | June 2018 | March 2022 | Allow | 45 | 3 | 1 | Yes | No |
| 15780762 | METHODS FOR PREDICTING RESPONSE TO ANTI-TNF THERAPY | June 2018 | March 2021 | Abandon | 33 | 1 | 1 | No | No |
| 15977443 | METHODS OF DIAGNOSING OR TREATING PROSTATE CANCER USING THE ERG GENE, ALONE OR IN COMBINATION WITH OTHER OVER OR UNDER EXPRESSED GENES IN PROSTATE CANCER | May 2018 | September 2021 | Allow | 40 | 2 | 1 | Yes | No |
| 15971461 | METHODS FOR DETECTING EPIGENETIC MODIFICATIONS | May 2018 | May 2020 | Allow | 25 | 1 | 1 | Yes | No |
| 15953875 | HYDROLYSIS PROBES | April 2018 | August 2020 | Abandon | 29 | 3 | 0 | Yes | Yes |
| 15766972 | METHOD FOR DIAGNOSING HEPATIC FIBROSIS BASED ON BACTERIAL PROFILE AND DIVERSITY | April 2018 | January 2021 | Abandon | 33 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KAPUSHOC, STEPHEN THOMAS.
With a 12.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 4.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KAPUSHOC, STEPHEN THOMAS works in Art Unit 1634 and has examined 739 patent applications in our dataset. With an allowance rate of 32.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner KAPUSHOC, STEPHEN THOMAS's allowance rate of 32.6% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KAPUSHOC, STEPHEN THOMAS receive 2.08 office actions before reaching final disposition. This places the examiner in the 51% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KAPUSHOC, STEPHEN THOMAS is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +57.2% benefit to allowance rate for applications examined by KAPUSHOC, STEPHEN THOMAS. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.4% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 29.0% of cases where such amendments are filed. This entry rate is in the 43% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 68.0% of appeals filed. This is in the 54% percentile among all examiners. Of these withdrawals, 94.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 74.4% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 81% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.8% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.